These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 12594937)

  • 41. [EUROGIN 2010: roadmap on cervical cancer prevention].
    Monsonego J
    Gynecol Obstet Fertil; 2011; 39(7-8):462-7. PubMed ID: 21764621
    [No Abstract]   [Full Text] [Related]  

  • 42. Success of vaccine offers promise of cervical cancer prevention.
    Schultz J
    J Natl Cancer Inst; 2003 Jan; 95(2):102-4. PubMed ID: 12529341
    [No Abstract]   [Full Text] [Related]  

  • 43. [A new strategy for prevention of cervical cancer approaching?].
    Skjeldestad FE
    Tidsskr Nor Laegeforen; 2001 Nov; 121(28):3263. PubMed ID: 11826455
    [No Abstract]   [Full Text] [Related]  

  • 44. Circulating human papillomavirus type 16 specific T-cells are associated with HLA Class I expression on tumor cells, but not related to the amount of viral oncogene transcripts.
    de Boer MA; Jordanova ES; van Poelgeest MI; van den Akker BE; van der Burg SH; Kenter GG; Fleuren GJ
    Int J Cancer; 2007 Dec; 121(12):2711-5. PubMed ID: 17724722
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HPV vaccine trial may take place in India.
    Sharma DC
    Lancet Oncol; 2002 Nov; 3(11):649. PubMed ID: 12424057
    [No Abstract]   [Full Text] [Related]  

  • 46. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
    Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
    Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Male circumcision, penile human papillomavirus infection, and cervical cancer.
    Bhimji A; Harrison D
    N Engl J Med; 2002 Oct; 347(18):1452-3; discussion 1452-3. PubMed ID: 12418039
    [No Abstract]   [Full Text] [Related]  

  • 48. [Perspectives for the development of vaccines and immunotherapy against cervico-uterine cancer].
    Guzmán-Rojas L; Alcocer-González JM; Madrid-Marina V
    Salud Publica Mex; 1998; 40(1):38-46. PubMed ID: 9567657
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multistep carcinogenesis and genital papillomavirus infection. Implications for diagnosis and vaccines.
    Rangel LM; Ramírez M; Torroella M; Pedroza A; Ibarra V; Gariglio P
    Arch Med Res; 1994; 25(2):265-72. PubMed ID: 7919824
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Molecular mechanism of carcinogenesis by human papillomavirus-16.
    Ishiji T
    J Dermatol; 2000 Feb; 27(2):73-86. PubMed ID: 10721654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene gun-mediated intracutaneous vaccination with papillomavirus E7 gene delays cancer development of papillomavirus-induced skin papillomas on rabbits.
    Han R; Peng X; Reed CA; Cladel NM; Budgeon LR; Pickel MD; Christensen ND
    Cancer Detect Prev; 2002; 26(6):458-67. PubMed ID: 12507231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Preventing cervical cancer.
    Cain JM; Howett MK
    Science; 2000 Jun; 288(5472):1753-5. PubMed ID: 10877694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
    Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
    Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Molecular interactions of 'high risk' human papillomaviruses E6 and E7 oncoproteins: implications for tumour progression.
    Chakrabarti O; Krishna S
    J Biosci; 2003 Apr; 28(3):337-48. PubMed ID: 12734411
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Consensus panel on cervical cancer highlights the HPV connection.
    McNeil C
    J Natl Cancer Inst; 1996 May; 88(9):575. PubMed ID: 8609653
    [No Abstract]   [Full Text] [Related]  

  • 56. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
    Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
    Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Primary prevention of uterine cervix cancer: focus on vaccine history and current strategy.
    Tewari KS; DiSaia PJ
    Obstet Gynecol Clin North Am; 2002 Dec; 29(4):843-68, ix. PubMed ID: 12509098
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cervical cancer vaccine trials started.
    AIDS Patient Care STDS; 2001 Apr; 15(4):229-30. PubMed ID: 11385762
    [No Abstract]   [Full Text] [Related]  

  • 59. Human papillomavirus. To screen or not to screen.
    Newkirk GR
    Arch Fam Med; 1993 Dec; 2(12):1227-8. PubMed ID: 8130902
    [No Abstract]   [Full Text] [Related]  

  • 60. Genital HPV: links to cervical cancer, treatment, and prevention.
    Perez LA
    Clin Lab Sci; 2001; 14(3):183-6; quiz 193. PubMed ID: 11517629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.